People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Other Technology, Biotechnology, Pharmaceuticals, Software / Tech, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Overhaul Group, Inc. | — | Other Technology | Series D+ | $225.7M | $909.2M | 2015 |
| Pulmatrix Inc | — | Biotechnology | Series B | $69.6M | $396.9M | 2015 |
| Pulmatrix, Inc. | — | Pharmaceuticals | Series B | $62.9M | $86.2M | 2015 |
| Kinaset Therapeutics, Inc. | — | Pharmaceuticals | Series B | $30.0M | $438.1M | 2020 |
| Swap Labs, Inc. | — | Software / Tech | Series A | $7.6M | $32.1M | 2023 |
| Alphageneron Pharmaceuticals, Inc. | — | Pharmaceuticals | Pre-Seed | $250K | $2.1M | 2023 |
| Arelant, Inc. | — | Other | Pre-Seed | $187K | $4.3M | 2015 |
Robert Clarke at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Clarke on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 2 | 23 |
| Terrance McGuire | 2 | 9 |
| Michael Higgins | 2 | 9 |
| SCOTT ROCKLAGE | 2 | 9 |
| Kurt Graves | 2 | 5 |
| David Maki | 2 | 2 |
| David Hava | 2 | 2 |
| Kevin Bitterman | 1 | 15 |
| Robert Brooks | 1 | 12 |
| Ryan Ziegler | 1 | 11 |
| Marc Lippman | 1 | 5 |
| Amit Munshi | 1 | 5 |
| TOM KING | 1 | 4 |
| Robert Connelly | 1 | 4 |
| Mark Iwicki | 1 | 4 |
| MICHAEL J. HIGGINS | 1 | 4 |
| Lauren T Silverman | 1 | 3 |
| Sameer Harish | 1 | 3 |
| Hojabr Alimi | 1 | 3 |
| David Edwards | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.